Will Adalimumab become ineffective after being used for a period of time?

Adalimumab is a fully humanized anti-TNF-α monoclonal antibody that is widely used to treat rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis and other autoimmune diseases. In the early stages of treatment, most patients can experience significant relief of symptoms and improvement in inflammatory indicators. However, some patients experience a weakening of the efficacy after using it for a period of time, which is called "secondary failure."

One of the main reasons for secondary failure of adalimumab is the development of drug resistance in the body, that is, the formation of anti-drug antibodies (ADA). These antibodies will bind to adalimumab and reduce its ability to bind to TNF-α, thus weakening the therapeutic effect. In addition, individual metabolic differences, disease progression, or other drug interference in some patients may also affect drug concentration and biological activity, resulting in a decrease in efficacy.

When a patient suspects that a drug has failed, doctors usually assess whether there is immune neutralization by testing blood drug concentrations and anti-drug antibody levels. If the efficacy is confirmed to be weakened, treatment strategies may be adjusted, such as increasing the dose, shortening the dosing interval, or combining immunosuppressants to reduce antibody production. In some cases, it may be necessary to switch to other biological agents, such as TNF inhibitors with different mechanisms or target drugs such as IL-17/IL-6.

Overall, although adalimumab has good efficacy in most patients, it does have a risk of losing efficacy after a period of use. Patients should review regularly during treatment, maintain communication with doctors, and detect changes in efficacy in a timely manner to facilitate early intervention and adjustment, thereby ensuring disease control and stability of quality of life.

Reference materials:https://www.drugs.com/

xa0